Vivos Therapeutics (VVOS) Other Non-Current Liabilities (2022 - 2026)

Vivos Therapeutics (VVOS) has 4 years of Other Non-Current Liabilities data on file, last reported at $1.3 million in Q1 2026.

• On a quarterly basis, Other Non-Current Liabilities changed N/A year-over-year to $1.3 million in Q1 2026; TTM through Mar 2026 was $1.3 million, a N/A change from a year earlier, with the FY2025 full-year figure at $1.3 million, changed N/A from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $1.3 million, roughly flat from $1.3 million in the prior quarter.
• Over the last five years, Other Non-Current Liabilities for VVOS reached as high as $2.2 million in Q2 2023 and fell as low as $101000.0 in Q1 2022.
• Historically, Other Non-Current Liabilities has averaged $1.2 million across 4 years, with a median of $1.3 million in 2023.
• On a YoY basis, Other Non-Current Liabilities climbed as much as 1219.8% in 2023 and fell as far as 1219.8% in 2023.
• Year by year, Other Non-Current Liabilities stood at $101000.0 in 2022, then soared by 494.06% to $600000.0 in 2023, then surged by 116.67% to $1.3 million in 2025, then changed by 0.0% to $1.3 million in 2026.
• Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $1.3 million in Q1 2026, $1.3 million in Q4 2025, and $1.4 million in Q3 2025.